TWST
TWST
US90184D1000
Twist Bioscience Corporation
Loading chart...

Company Profile

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc and Lilly TuneLab. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Latest News

Related stocks

CAI
CAI • United States
Caris Life Sciences, Inc.
29.7 USD
8.39B USD 1Y -16.5%
KYMR
KYMR • United States
Kymera Therapeutics, Inc.
112.4 USD
9.35B USD 1Y +94.2%
MANE
MANE • United States
Veradermics, Incorporated
130.9 USD
5.47B USD
KOD
KOD • United States
Kodiak Sciences Inc
99.87 USD
6.28B USD 1Y +551.9%
DFTX
DFTX • United States
Definium Therapeutics, Inc.
36.9 USD
4.96B USD 1Y +166.8%
RYTM
RYTM • United States
Rhythm Pharmaceuticals, Inc.
90.78 USD
6.23B USD 1Y -10.6%
TGTX
TGTX • United States
TG Therapeutics, Inc.
55.37 USD
8.48B USD 1Y +49.2%
PTGX
PTGX • United States
Protagonist Therapeutics, Inc.
143.73 USD
9.3B USD 1Y +114.3%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
78.2% p.a.
Max Drawdown (5Y)
-91.5%
Sharpe Ratio (5Y)
0.08
Beta Factor
2.19
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Unprofitable business model: The company is currently generating net losses.
High market risk: Beta of 2.19 indicates above-average volatility compared to the broader market.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (78.2% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -94.5% in the extended horizon.
ende